The proposed study will be a 24-week intervention with a 12-month follow-up period to evaluate the impact of contingency management with stepped care to pre-exposure prophylaxis (PrEP) adherence and support services (CoMPASS) to promote HIV prevention among individuals with opioid use disorder who have injected drugs in their lifetime. In parallel, the investigators will conduct an implementation focused process evaluation to inform real-world implementation of CoMPASS. .
Consistent with a Hybrid Effectiveness-Implementation Type 1 design, this is a multi-site randomized clinical trial designed to evaluate the effectiveness of Contingency Management with stepped care to PrEP Adherence and Support Services (CoMPASS) vs. treatment as usual (TAU) on HIV risk reduction among individuals with opioid use disorder (OUD) who have injected drugs in their lifetime. The study will be conducted in community-based settings serving individuals with opioid use disorder to assess the effectiveness of CoMPASS on promoting: sustained PrEP adherence (primary outcome) and HIV risk behaviors, engagement in opioid use disorder-related care, opioid use (secondary outcomes); and sexually transmitted infections and HIV (exploratory). Participants randomized to CoMPASS will first receive contingency management and have the potential to earn prizes for making progress towards initiation of and consistent adherence to HIV pre-exposure prophylaxis (PrEP) and engagement in OUD-related care. Individuals who do not demonstrate PrEP adherence (based on self-report, confirmed by urine testing for tenofovir metabolites at week 12), will be "stepped up" to PrEP Adherence and Support Services (PASS). The intervention is 24 weeks in duration. Participants randomized to TAU will receive a health handout on HIV risk reduction approaches, including PrEP and OUD-related care, and where to access such services. To inform future implementation efforts, factors relevant for scale-up in parallel (e.g., completion of study visits, attitudes regarding the intervention among front-line staff) will be assessed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
526
Participants will receive contingency management sessions (n=9). Participants who do not demonstrate PrEP adherence by week 12 will be "stepped up" to receive PrEP adherence and support services (n=5).
Recovery Network of Programs, Inc
Bridgeport, Connecticut, United States
TERMINATEDLiberations Program, Inc
Bridgeport, Connecticut, United States
RECRUITINGApex Community Care. Inc.
Danbury, Connecticut, United States
TERMINATEDGreater Hartford Harm Reduction Coalition- SWAN
New Haven, Connecticut, United States
RECRUITINGAPT
New Haven, Connecticut, United States
RECRUITINGStanley Street Treatment and Resource Center
Fall River, Massachusetts, United States
RECRUITINGSustained PrEP adherence
Determined by tenovifir-diphosphate levels by dried blood spot testing.
Time frame: 24 weeks
Sustained PrEP adherence
Determined by tenovifir-diphosphate levels by dried blood spot testing. .
Time frame: 12 weeks
Recent PrEP adherence
Self-report adherence confirmed by the presence of tenofivir in urine sample.
Time frame: 12 weeks
HIV Risk Behaviors
Self-reported HIV risk behaviors
Time frame: 12 weeks
HIV Risk Behaviors
Self-reported HIV risk behaviors
Time frame: 24 weeks
Engagement in opioid use disorder-related care
Self report of engagement in opioid use disorder-related care
Time frame: 12 weeks
Engagement in opioid use disorder-related care
Self report of engagement in opioid use disorder-related care
Time frame: 24 weeks
Extra medical opioid use
Self reported extra medical opioid use
Time frame: 12 weeks
Extra medical opioid use
Self reported extra medical opioid use
Time frame: 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.